Instrument Inactif

Autres langues ONCODESIGN

Actions

ALONC

FR0011766229

Recherche biotechnologique et médicale

Autres langues

21/12/22	Oncodesign Société Anonyme(ENXTPA:ALONC) dropped from Next Biotech Index
06/12/22	Bolsa de Madrid: Es la economía, estúpido
26/10/22	ONCODESIGN : Franchissement de seuil
19/10/22	Oncodesign Services Names Successors as Chairman/CEO Departs
19/10/22	Oncodesign Services Shareholders Sell Majority Stake to Edmond de Rothschild Fund
19/10/22	ONCODESIGN : Inside Information / Operations of the issuer (acquisitions, sales...)
05/10/22	Oncodesign Precision Medicine to List Directly on Euronext Access + Paris
05/10/22	Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.
05/10/22	Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.
03/10/22	The General Meeting of Oncodesign authorises the allocation of Oncodesign Precision Medicine shares to Oncodesign shareholders
29/09/22	Euronext Paris authorises the listing of Oncodesign Precision Medicine shares on Euronext Access + in connection with the allocation of OPM shares to Oncodesign shareholders
29/09/22	Oncodesign Unit Gains Approval To List On Euronext Access + In Paris
28/09/22	Oncodesign Société Anonyme agreed to Spin-Off Oncodesign Precision Medicine.
27/09/22	Parkinson, Servier exercises the exclusive licensing option on collaborative program with Oncodesign Precision Medicine
15/09/22	Oncodesign : announces its results for the first half of 2022
01/07/22	Oncodesign Société Anonyme Announces Planned Separation of Its Two Business Areas
07/04/22	Oncodesign Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021
08/02/22	Sengine Precision Medicine and Oncodesign Announce Collaboration Agreement for the Discovery of New Personalized Cancer Treatment for Aggressive and Untreatable Tumors
27/01/22	Oncodesign Société Anonyme Reports Turnover Results for the Year Ended December 31, 2021
24/12/21	Oncodesign Société Anonyme's Equity Buyback announced on February 15, 2021, has expired.
04/11/21	Oncodesign Strengthens the Intellectual Property of ODS 101 in Treating Inflammatory Bowel Disease
26/10/21	Oncodesign : Appoints Chief Development Officer
25/10/21	Oncodesign Appoints Karine Lignel as Group Chief Development Officer
21/10/21	Oncodesign : Starts R&D Deal with TiumBio for Fibrosis Drug Candidates
21/10/21	Oncodesign and TiumBio Sign Collaboration Agreement for R&D of Fibrosis Drug Candidates